American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 723-725 , May 2009

Statin Effects in CKD: Is There a “Point of No Return”?

  • Christoph Wanner, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Christoph Wanner, MD, University of Würzburg, Division of Nephrology, University Hospital Würzburg, Germany

References 

  1. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  2. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet. 2008;371:117–125
  3. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP ALLIANCE Investigators. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009;53:741–750
  4. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–1563
  5. Shepherd J, Kastelein JJP, Bittner V, et al. TNT (Treating to New Targets) Investigators Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The Treating to New Targets (TNT) Study. J Am Coll Cardiol. 2008;51:1448–1454
  6. Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16:3748–3754
  7. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  8. Baigent C, Landray MJ, Wheeler DC. Misleading associations between cholesterol and vascular outcomes in dialysis patients: The need for randomized trials. Semin Dial. 2007;20:498–503
  9. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  10. Fathi R, Isbel N, Short L, et al. The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis. 2004;43:45–52

PII: S0272-6386(09)00397-7

doi: 10.1053/j.ajkd.2009.02.002

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 723-725 , May 2009

Article Tools